
price close busi octob
labcorp lead refer laboratori test
compani also oper covanc drug develop
chiltern
laboratori corpor america hold
diagnost tool
lh deliv anoth mix quarter bid farewel
longtim ceo dave king hold pt
labcorp deliv anoth mix quarter ceo dave king last quarterli earn
call applaud work dave king done lh also lab
industri acla larg lh deliv mix result affirm neutral
stanc stock compani continu face pressur relat pama
reimburs side volum loss commerci contract side howev
lh signal manag care contract stabl covanc deliv mid-to-
high singl digit revenue growth though slightli miss estim acknowledg lh
reason valu consensu earn think fair valuat
attribut stock ytd return year inclus index
discount multipl index reiter hold trim pt
use multipl adj ep
rev y/i beat street
thank beat diagnost divis partial off-set miss covanc adj
ep y/i beat street
labcorp diagnost dx rev y/i swung back modest growth
beat street volum revenue /req beat
estim total volum beat thank growth
acquisit organ volum growth manag indic organ
volum grew despit impact relat chang mang care contract
slightli greater impact competitor quest expect
share gain continu lh lh character volum relat health plan
chang stabl rev/req beat estim
covanc covanc rev y/i miss street
major point growth came organ covanc
growth grew partial off-set disposit relat
invigo fx said adj om covanc grew solid
y/i help off-set adj om declin labcorp diagnost covanc backlog
exit lh expect backlog
convert revenu ntm
tighten guid lh rais low end revenu guid
y/i rais diagnost revenue guid
lh lower high end covanc revenue growth guid y/
includ increment headwind fx
year lh narrow adj ep guid
y/i vs our/street prior lh maintain
guid
chang dtc test outlook lh spend much time talk direct-
to-consum busi reiter similar commentari
expect busi flat manag specif
call lh indic deliv first y/i declin mark
drag lh organ volum remain cautiou recoveri dtc
test space given concern relat privaci clinic util name two
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
laboratori corpor america hold
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price octob
diagnost tool
laboratori corpor america hold
hold unchang target price octob
diagnost tool
laboratori corpor america hold
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research iii best author analyst
knowledg she/h receipt materi non-publ inform issuer
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin octob et
date time product octob et
laboratori corpor america hold lh
pt use multipl adj ep estim
pt use multipl adj ep estim y/i
risk achiev target price valuat
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
hold unchang target price octob
diagnost tool
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
